Aurinia Pharmaceuticals, Inc. (AUPH)
13.95
-0.42
(-2.92%)
USD |
NASDAQ |
Mar 13, 16:00
13.95
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Enterprise Value : 1.532B for March 13, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xenon Pharmaceuticals, Inc. | 4.054B |
| Oncolytics Biotech, Inc. | 97.61M |
| Edesa Biotech, Inc. | 46.92M |
| Lexaria Bioscience Corp. | 12.71M |
| ProMIS Neurosciences, Inc. | 23.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 210.79M |
| Revenue (Quarterly) | 77.11M |
| Total Expenses (Quarterly) | -133.68M |
| EPS Diluted (Quarterly) | 1.526 |
| Gross Profit Margin (Quarterly) | 88.59% |
| Earnings Yield | 14.89% |
| Operating Earnings Yield | 6.00% |
| Normalized Earnings Yield | 14.95 |